AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02106923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/2 tablets Metformin XR
Description: Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
Study NCT02106923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Empagliflozin/1000 mg Metformin XR
Description: Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
Study NCT02106923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
Description: Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INERT OIL
Description: Non-iodised evening primrose oil capsule; oral route; once at study start
Study NCT02106923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 tablets 5 mg Empagliflozin/750 Metformin XR
Description: Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
Study NCT02134028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
Study NCT02503865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
Description: Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
Study NCT02503865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication
Description: Vegetable and salt diet
Study NCT03246594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of oesophageal probe for temperature measurement
Description: The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
Study NCT03246594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power limitation of RF generator
Description: no probe utilized; Limit the RF Generator Output to 25W
Study NCT03730701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention program for stroke
Description: The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
Study NCT01401244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
Study NCT01401244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
Study NCT03477916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: fecal microbial transplantation (FMT)
Study NCT03477916 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo FMT
Description: Placebo fecal microbial transplantation (FMT)
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: INERT OIL
Description: Non-iodised evening primrose oil capsule; oral route; once at study start
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INERT MNP
Description: Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NON-IODISED MNP
Description: Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Study NCT02272803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT03477916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic Fiber
Description: combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
Study NCT02272803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Study NCT02272803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02272803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02272803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608)
Study NCT00834561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 200 mg Tablet
Study NCT03477916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotic Fiber
Description: combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
Study NCT03477916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cellulose
Description: Cellulose
Study NCT03477916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose
Description: Cellulose
Study NCT00816946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced education
Description: Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI
Study NCT03163238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
Study NCT03163238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
Study NCT00077454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally (PO)
Study NCT00077454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT00077454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00077454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00009867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study NCT00330824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic/steroid combination
Description: 1gtt, 4x/d, 15 days
Study NCT00330824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin/dexamethasone
Description: 1gtt, 4x/days, 15 days
Study NCT03990948 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sample collection
Study NCT02333539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence behaviors and recommendations for improvement.
Study NCT02333539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence behavior that needs improvement is targeted
Study NCT03742804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral G100
Description: G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
Study NCT03306771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Duplex
Description: The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
Study NCT03427775 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: multimodal perioperative pain protocol (MP3)
Description: administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
Study NCT02194296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride - lozenge
Study NCT02194296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup
Study NCT00834561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: 200 mg Tablet
Study NCT03674619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior discectomy
Description: Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
Study NCT03674619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
Study NCT04290546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-15 Superagonist (N-803)
Description: -- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight.
Study NCT04290546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIML NK cell Infusion
Description: (Dose 0 or -1) infused on Day 0
Study NCT04290546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: single dose of lead-in ipilimumab via iv per protocol determined dose
Study NCT02837484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NuTech Affinity™ Membrane
Description: NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
Study NCT03915860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene
Description: Topical Cream
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00677053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study NCT00609362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: one tablet of rosiglitazone 8 milligrams per day for 14 weeks
Study NCT00609362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: One encapsulated placebo pill a day for 14 weeks
Study NCT01774370 — intervention group
Intervention type: DRUG
Intervention: Pradaxa (Dabigatran etexilate mesilate)
Description: 110 mg or 150 mg b.i.d.
Study NCT03051009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg
Study NCT03051009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50 μg
Study NCT00968942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Study NCT00968942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Study NCT01895647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
Study NCT03870022 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor System
Description: Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
Study NCT02697422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based peer health coach intervention
Description: The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
Study NCT02273453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songha® Night
Study NCT02273453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam
Study NCT02273453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02273453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03030209 — intervention group
Intervention type: PROCEDURE
Intervention: Distal pancreatectomy
Description: Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
Study NCT02555098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire contact lenses
Description: Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
Study NCT02555098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A contact lenses
Description: Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
Study NCT03186924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND for health
Description: The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
Study NCT01982227 — intervention group
Intervention type: DRUG
Intervention: indocyanine green
Description: intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
Study NCT03501277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.
Study NCT03501277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study NCT03870022 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Similar Carbon Monoxide breath sensor system
Description: Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
Study NCT04101422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 1
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
Study NCT04101422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 2
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
Study NCT04101422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 3
Description: Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
Study NCT04101422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality 4
Description: Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
Study NCT03505242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchial blocker for BB group
Description: Using bronchial blocker to block right middle lower lobe during surgery.
Study NCT03505242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube for DLT group
Description: Using double lumen tube to achieve single lung ventilation during surgery.
Study NCT01565746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Study NCT04290546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting day +15, every 14 days for 8 total doses via IV per protocol
Study NCT01733797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wooden spatula
Description: Lollipop sticks placed between incisors
Study NCT01733797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therabite
Description: Hand held device placed in mouth that exercises the jaw
Study NCT01525901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin-Like Growth Factor-1 (IGF-1)
Description: IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
Study NCT01525901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline solution will be administered for three months subcutaneously.
Study NCT03745963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Description: Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
Study NCT03745963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% oral sucrose
Description: Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
Study NCT03916393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 20 mg
Description: PF-06651600 in four (4) different oral formulations will be administered in different periods.